Publications
CER Interview with Dan Ollendorf
| Type: | Podcast |
| Date: | January 4, 2012 |
| Related Topics: | Aging Research, Drug Development, Drug Safety, Medical Innovation, Policy, Research, Vision Loss |
Dan Ollendorf, MPH, ARM , is Chief Review Officer for the Institute of Clinical and Economic Review (ICER); in this capacity, he is responsible for the conduct of systematic reviews of the comparative effectiveness of new or emerging health care technologies, as well as the coordination and oversight of the broader health technology assessment process. Dan’s 25 years of health care experience include work in the insurance, managed care, hospital, informatics, and consulting sectors, the last 15 years of which have been spent conducting health-economic, epidemiologic, and other relevant evaluations for a variety of stakeholders.
Prior to joining ICER, Dan was Executive Director, Health Economics and Outcomes Research, for IMS Health, where he was responsible for the operations and strategy of a $20 million franchise as well as the successful acquisition and integration of a US consulting practice. Dan has also served as Vice President of Applied Research at PharMetrics (now a unit of IMS), where he managed the scientific team conducting a variety of research initiatives using integrated claims data; and as a senior consultant at Policy Analysis Inc. (PAI), where he was responsible for the conduct and design of numerous health-economic, quality-of-life, and retrospective database analyses in a variety of therapeutic areas.
Dan holds a Master’s of Public Health in epidemiology/biostatistics and health services from Boston University, an Associate’s degree in Risk Management from the Insurance Institute, and a Bachelor of Arts in Health Administration from the University of Rochester. He has authored over 40 peer-reviewed articles, is a reviewer for several medical-scientific journals, and currently serves on the editorial advisory board of the Journal of Managed Care Pharmacy.
Tweet
Prior to joining ICER, Dan was Executive Director, Health Economics and Outcomes Research, for IMS Health, where he was responsible for the operations and strategy of a $20 million franchise as well as the successful acquisition and integration of a US consulting practice. Dan has also served as Vice President of Applied Research at PharMetrics (now a unit of IMS), where he managed the scientific team conducting a variety of research initiatives using integrated claims data; and as a senior consultant at Policy Analysis Inc. (PAI), where he was responsible for the conduct and design of numerous health-economic, quality-of-life, and retrospective database analyses in a variety of therapeutic areas.
Dan holds a Master’s of Public Health in epidemiology/biostatistics and health services from Boston University, an Associate’s degree in Risk Management from the Insurance Institute, and a Bachelor of Arts in Health Administration from the University of Rochester. He has authored over 40 peer-reviewed articles, is a reviewer for several medical-scientific journals, and currently serves on the editorial advisory board of the Journal of Managed Care Pharmacy.
“In terms of policymakers, I think the concern is…what sorts of other head-to-head trials should be conducted in similar situations where there may be an older stand-by or a product that has kind of been subsumed by the process of innovation, but may actually in fact still have relatively high effectiveness versus a comparative treatment.”
Tweet
This podcast series provides expert reactions to the CATT trial data in terms of what it will mean for wAMD patients and professionals, and its potential impact on future trials, policies and innovation.
To listen to interviews on this topic with other experts, click here.
To listen to interviews on this topic with other experts, click here.
Living Longer and Loving It!
Sign up for the Alliance's quarterly newsletter and get timely information on advancements in science, treatment, and health policy that help you "Live Longer and Love It."